Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)973.70K
Market Cap
$213.41M
Enterprise Value$76.62M
Total Cash (Recent Filing)$99.81M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 05, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding108,332,214
10 Day Avg. Volume761,060
30 Day Avg. Volume973,701
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue4.56
Enterprise Value/Gross Profit18.88
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$7.92Price Target Upside306.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentATI-2138 clinical proof-of-concept data looks promising, providing evidence that the drug can offer efficacy comparable to approved treatments with improved tolerability.
Growth OpportunitiesAclaris Therapeutics intends to further develop ATI-2138 for alopecia areata and explore other indications, suggesting potential future growth opportunities.
Safety ProfileThe favorable safety profile of ATI-2138, if sustained, is expected to provide a key competitive advantage against approved JAK inhibitors.
Bears Say
Investor ConcernsInvestors should be aware of potential conflicts of interest as Wedbush Securities seeks to do business with companies covered in its research reports.
Research And Development RisksMultiple other pipeline programs ongoing, any of which could drive meaningful long-term upside.
Study DesignCompared to the atopic dermatitis clinical landscape, '2138's treatment effect is competitive, though the study's design and sample size are noted.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $213.41M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 52 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.003.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 108,332,214 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
Aclaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.92 (306.15% Upside)
$7.92 (306.15% Upside)
Hedge Fund Trend
Decreased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.94%
12-Months-Change
Fundamentals
Return on Equity
-101.41%
Trailing 12-Months
Asset Growth
17.43%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$7.92
▲(306.15% Upside)
Technical Analysis
Ownership Overview
2.95% Insiders
6.21% Mutual Funds
46.25% Other Institutional Investors
33.26% Public Companies and
Individual Investors